Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men.

Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM.

AIDS Behav. 2018 May 12. doi: 10.1007/s10461-018-2151-0. [Epub ahead of print]

PMID:
29754268
2.

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis.

Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY.

AIDS Patient Care STDS. 2018 Mar;32(3):104-111. doi: 10.1089/apc.2017.0255.

3.

Knowledge, Practices, and Barriers to HIV Preexposure Prophylaxis Prescribing Among Washington State Medical Providers.

Wood BR, McMahan VM, Naismith K, Stockton JB, Delaney LA, Stekler JD.

Sex Transm Dis. 2018 Jul;45(7):452-458. doi: 10.1097/OLQ.0000000000000781.

PMID:
29465664
4.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

PMID:
29415175
5.

HIV Pre-exposure Prophylaxis Prescribing Through Telehealth.

Stekler JD, McMahan V, Ballinger L, Viquez L, Swanson F, Stockton J, Crutsinger-Perry B, Kern D, Scott JD.

J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):e40-e42. doi: 10.1097/QAI.0000000000001621. No abstract available.

PMID:
29280768
6.

HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.

Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM, For The iPrEx Study Team.

AIDS Care. 2018 Apr;30(4):466-472. doi: 10.1080/09540121.2017.1394437. Epub 2017 Oct 28.

7.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

PMID:
28639995
8.

Risk, safety and sex among male PrEP users: time for a new understanding.

Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, Hosek S, Grant R.

Cult Health Sex. 2017 Dec;19(12):1301-1313. doi: 10.1080/13691058.2017.1310927. Epub 2017 Apr 18.

PMID:
28415911
9.

SEXUAL PRACTICES AMONG MEN WHO HAVE SEX WITH MEN IN CHIANG MAI, THAILAND: PART OF THE ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS TRIAL.

Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Guptarak M, Saokhieo P, Sangangamsakun T, Songsupa R, McMahan V, Grant R.

Southeast Asian J Trop Med Public Health. 2016 May;47(3):514-27.

PMID:
27405136
10.

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.

Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM.

AIDS Behav. 2016 Jul;20(7):1527-34. doi: 10.1007/s10461-016-1415-9.

11.

Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study.

Amico KR, Mehrotra M, Avelino-Silva VI, McMahan V, Veloso VG, Anderson P, Guanira J, Grant R; iPrEx Study Team.

AIDS Behav. 2016 Jul;20(7):1535-40. doi: 10.1007/s10461-016-1360-7.

12.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

13.

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM; iPrEx investigators.

Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.

14.

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.

Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM; iPrEx Study Team.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):281-6. doi: 10.1097/QAI.0000000000000857. Erratum in: J Acquir Immune Defic Syndr. 2016 Jul 1;72 (3):e82.

15.

Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8379-84. doi: 10.1073/pnas.1501443112. Epub 2015 Jun 22.

16.

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).

Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM; iPrEx Study Team.

AIDS Behav. 2016 Jul;20(7):1478-88. doi: 10.1007/s10461-015-1082-2.

17.

Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.

Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, Hosek S, Mayer KH, Grant RM.

AIDS Care. 2015;27(10):1199-204. doi: 10.1080/09540121.2015.1039958. Epub 2015 May 22.

PMID:
26001026
18.

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM; Preexposure Prophylaxis Initiative Study Team.

Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.

19.

Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.

Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R; iPrEx Study team.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):528-37. doi: 10.1097/QAI.0000000000000351.

20.

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV; iPrEx study team.

Lancet Infect Dis. 2014 Sep;14(9):820-9. doi: 10.1016/S1473-3099(14)70847-3. Epub 2014 Jul 22.

PMID:
25065857
21.

Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.

Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM; iPrEx Study Team.

Clin Infect Dis. 2014 Oct;59(7):1020-6. doi: 10.1093/cid/ciu450. Epub 2014 Jun 13.

22.

Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.

Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):530-7. doi: 10.1097/QAI.0000000000000216.

23.

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM; iPrEx Study Team.

J Infect Dis. 2014 Oct 15;210(8):1217-27. doi: 10.1093/infdis/jiu233. Epub 2014 Apr 16.

24.

Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.

Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant RM.

PLoS One. 2014 Mar 17;9(3):e91513. doi: 10.1371/journal.pone.0091513. eCollection 2014.

25.

HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.

Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM.

Lancet Infect Dis. 2014 Jun;14(6):468-75. doi: 10.1016/S1473-3099(14)70025-8. Epub 2014 Mar 7.

26.

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.

Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, Guanira JV, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Burns DN, Grant RM; iPrEx Study Team.

AIDS. 2014 Mar 27;28(6):851-9. doi: 10.1097/QAD.0000000000000156.

27.

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.

PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997. eCollection 2013.

28.

Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Gilmore HJ, Liu A, Koester KA, Amico KR, McMahan V, Goicochea P, Vargas L, Lubensky D, Buchbinder S, Grant R.

AIDS Patient Care STDS. 2013 Oct;27(10):560-6. doi: 10.1089/apc.2013.0116.

29.

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM; iPrEx Study Team.

Sci Transl Med. 2012 Sep 12;4(151):151ra125.

30.

Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.

R Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, Liu A.

AIDS Behav. 2012 Jul;16(5):1243-59. doi: 10.1007/s10461-012-0182-5.

PMID:
22460228
31.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

32.

Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, Grant RM, Nixon DF.

Clin Vaccine Immunol. 2008 Nov;15(11):1745-8. doi: 10.1128/CVI.00247-08. Epub 2008 Sep 24.

Supplemental Content

Loading ...
Support Center